News Room

PR & Blog | Events | Media | Publications

Indication

Geography

Pre-Clinical Research

Feasibility Trial

Pivotal Trial

Marketing Authorization

Skin Cancer

US

 0/100 %
Recruiting patients for cutaneous squamous cell carcinoma trial in the United States

PR & Blog

Press Releases

  • Press Releases

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Read More
  • Press Releases

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Read More
  • Press Releases

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study’s Pre-Specified Threshold for Success

Read More
  • Press Releases

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Read More
  • Press Releases

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Read More
  • Press Releases

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

Read More
  • Press Releases

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Read More
  • Press Releases

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

Read More
  • Press Releases

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Read More
  • Press Releases

Alpha Tau to Participate in May Investor Conferences

Read More
  • Press Releases

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed

Read More
  • Press Releases

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

Read More
  • Press Releases

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

Read More
  • Press Releases

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute

Read More
  • Press Releases

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

Read More
  • Press Releases

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

Read More
  • Press Releases

Alpha Tau Announces Presentation of New Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT® Pancreatic Cancer Studies

Read More
  • Press Releases

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

Read More
  • Press Releases

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

Read More
  • Press Releases

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

Read More
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
  • Press Releases

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Read More
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
  • Press Releases

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Read More
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
  • Press Releases

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Read More
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
  • Press Releases

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Read More
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
  • Press Releases

Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

Read More
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
  • Press Releases

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Read More
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
  • Press Releases

Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium

Read More

Blog

  • Blog

Five Takeaways from AHNS 2026: Alpha DaRT in Combination with Immunotherapy for Advanced Head and Neck Cancer

Read More
  • Blog

Re-examining Liver Tumor Response with Intratumoral Alpha Radiotherapeutics – A Three-Way Conversation on a Landmark New Preclinical Study in Colorectal Liver Metastases

Read More
  • Blog

Alpha DaRT® and Checkpoint Inhibitors: Igniting the Immune System for a Cancer Care Breakthrough

Read More
Interview with Dr. Mark D'Andrea - Understanding Pancreatic Cancer
  • Blog

Interview with Dr. Mark D’Andrea – Understanding Pancreatic Cancer

Read More
Interview with Dr. Harold Jacob on Alpha DaRT for Pancreatic Cancer
  • Blog

Interview with Dr. Harold Jacob on Alpha DaRT for Pancreatic Cancer

Read More
Alpha DaRT Investigator Meeting in Las Vegas
  • Blog

Alpha DaRT Investigator Meeting in Las Vegas

Read More
Lela’s Story of her Cancer Treatment Journey that Brought her to Alpha DaRT
  • Blog

Lela’s Story of her Cancer Treatment Journey that Brought her to Alpha DaRT

Read More
Alpha-emitting Radiation Therapy Could Create a Paradigm Shift in Cancer Treatment
  • Blog

Alpha-emitting Radiation Therapy Could Create a Paradigm Shift in Cancer Treatment

Read More
Alpha Tau Honors the Birthday of Niels Bohr - Pioneering Theoretical Physicist and Great Humanitaria
  • Blog

Alpha Tau Honors the Birthday of Niels Bohr – Pioneering Theoretical Physicist and Great Humanitaria

Read More
Alpha DaRT: Turning alpha radiation into a high-precision cancer therapy
  • Blog

Alpha DaRT: Turning alpha radiation into a high-precision cancer therapy

Read More
  • Blog

Five Takeaways from AHNS 2026: Alpha DaRT in Combination with Immunotherapy for Advanced Head and Neck Cancer

Read More
  • Press Releases

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Read More
  • Press Releases

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Read More
  • Press Releases

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study’s Pre-Specified Threshold for Success

Read More
  • Press Releases

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Read More
  • Blog

Re-examining Liver Tumor Response with Intratumoral Alpha Radiotherapeutics – A Three-Way Conversation on a Landmark New Preclinical Study in Colorectal Liver Metastases

Read More
  • Press Releases

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Read More
  • Press Releases

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

Read More
  • Press Releases

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Read More
Load More

Events & Presentations

Upcoming events

American Society for Radiotherapy and Oncology

ASTRO 2026

May 15, 2026
- September 30, 2026
Thomas M. Menino Convention and Exhibition Center, Boston, Massachusetts
Booth: 1652

Past events

American Head and Neck Society

American Head and Neck Society’s 12th International Conference on Head and Neck Cancer

July 19, 2026
- July 21, 2026
Menino Convention and Exhibition Center (formerly known as the Boston Convention and Exhibition Center) Boston, Massachusetts

European Society for Radiotherapy and Oncology

ESTRO 2026

May 15, 2026
- May 19, 2026
Stockholm, Sweden
Booth: Alpha Tau

American Society for Radiotherapy and Oncology

ASTRO 2026

May 15, 2026
- September 30, 2026
Thomas M. Menino Convention and Exhibition Center, Boston, Massachusetts
Booth: 1652

Digestive Disease Week®

Digestive Disease Week® (DDW) 2026

May 2, 2026
- May 5, 2026
McCormick Place (West Building) in Chicago, Illinois.
Booth: 3754

Publications

Filter by Publication Category
Select Publication Caterories
Filter by Publication Category
Filter by Publication Journal
Select Publication Journals
Filter by Publication Journal
Filter by Publication Year
Select Years
Filter by Publication Year

Physics

Diffusion of the alpha-particle emitting daughters of alpha-DaRT sources in an orthotopic murine model of colorectal adenocarcinoma

2026
Author: Cyr Mélodie, et al.
View Publication

Pre-Clinical

Effect of intratumoral alpha radiation on tumor growth delay and tumor microenvironment in an orthotopic colorectal liver metastasis murine model

2026
Author: Zlotkin O, et al.
View Publication

Physics

Exploring the therapeutic potential of localized alpha irradiation for cancer: from DNA damage to immune activation

2026
Author: Deufel LC, et al.
View Publication

Review

Exploring the therapeutic potential of localized alpha irradiation for cancer: from DNA damage to immune activation

2025
Author: Hazout S, et al.
View Publication

Physics

Clinical Best Practices for Radiation Safety During an Alpha DaRT Treatment

2025
Author: Cohen Y, et al.
View Publication

Pre-Clinical

Stereotactic implantation of diffusing alpha-emitters radiationtherapy sources in the swine brain: a potential new focal therapy forbrain tumors

2025
Author: Shoshan Y, et al.
View Publication

Pre-Clinical

DNA damage response in a 2D-culture model by diffusing alpha-emitters radiation therapy (Alpha-DaRT)

2024
Author: Nojima H, et al.
View Publication

Clinical

Extended Follow-Up Outcomes from Pooled Prospective Studies Evaluating Efficacy of Interstitial Alpha Radionuclide Treatment for Skin and Head and Neck Cancers

2024
Author: Popovtzer A, et al.
View Publication

Clinical

Feasibility and safety of endoscopic ultrasound-guided diffusing alpha emitter radiation therapy for advanced pancreatic cancer…

2024
Author: Miller CS, et al.
View Publication

Review

Using Alpha Particles to Treat Solid Tumors

2023
Author: Heard S, et al.
View Publication

Physics

A finite element method for modeling diffusion of alpha-emitting particles in tissue

2023
Author: Zhang IP, et al.
View Publication

Physics

The low-LET radiation contribution to the tumor dose in diffusing alpha-emitters radiation therapy

2023
Author: Epstein L, et al.
View Publication

Physics

Bronchoscopic deployment and implantation of Diffusingalpha-emitters Radiation Therapy into the lung and mediastinumfor treatment of lung cancer: a pre-clinical safety and feasibilitystudy

2023
Author: Sadoughi A, et al.
View Publication

Clinical

Feasibility and Safety of Diffusing Alpha-Emitter Radiation Therapy for Recurrent or Unresectable Skin Cancers

2023
Author: D’Andrea MA, et al.
View Publication

Clinical

Alpha DaRT technology harnessing the power of alpha particles for therapeutic use in fighting vulvar cancer

2023
Author: Mizrachi A, et al.
View Publication

Pre-Clinical

A New Approach for a Safe and Reproducible Seeds Positioning for Diffusing Alpha-Emitters Radiation Therapy of Squamous Cell Skin Cancer: A Feasibility Study

2022
Author: Feliciani G, et al.
View Publication

Pre-Clinical

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts

2022
Author: Nishri Y, et al.
View Publication

Physics

Alpha dose modeling in diffusing alpha-emitters radiation therapy. Part II: Lattice studies

2022
Author: Heger G, et al.
View Publication

Physics

Alpha dose modeling in diffusing alpha-emitters radiationtherapy—Part I: single-seed calculations in one and twodimensions

2022
Author: Heger G, et al.
View Publication

Pre-Clinical

Diffusing alpha-emitters radiation therapy Promotes a Proimmunogenic Tumor Microenvironment and Synergizes With Programmed Cell Death Protein 1 Blockade

2022
Author: Del Mare S, et al.
View Publication

Pre-Clinical

The Potentiation of Anti‐Tumor Immunity by Tumor Abolition with Alpha Particles, Protons, or Carbon Ion Radiation and Its Enforcement by Combination withImmunoadjuvants or Inhibitors of Immune Suppressor Cells and Checkpoint Molecules

2021
Author: Keisari Y, et al.
View Publication

Pre-Clinical

RIG-1-Like Receptor Activation Synergizes With Intratumoral Alpha Radiation to Induce Pancreatic Tumor Rejection, Triple-Negative Breast Metastases Clearance, and Antitumor Immune Memory in Mice

2020
Author: Domankevich V, et al.
View Publication

Physics

Diffusing alpha-emitters radiation therapy: approximate modeling of themacroscopic alpha particle dose of a point source

2020
Author: Arazi A
View Publication

Review

Effective treatment of metastatic cancer by an innovative intratumoral alpha particle-mediated radiotherapy in combination with immunotherapy: A short review

2020
Author: Keisari Y, et al.
View Publication

Clinical

Initial Safety and Tumor Control Results from a “First-in-Human” Multicenter Prospective Trial Evaluating a Novel Alpha-Emitting Radionuclide for the Treatment of Locally Advanced Recurrent Squamous Cell Carcinomas of the Skin and Head and Neck

2020
Author: Popovtzer A, et al.
View Publication

Clinical

A Hard Target Needs a Sharper DaRT

2020
Author: Den RB, et al.
View Publication

Pre-Clinical

Combining alpha radiation‑based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor‑specific long‑term immune response

2019
Author: Domankevich V, et al.
View Publication

Clinical

Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report

2019
Author: Bellia SR, et al.
View Publication

Pre-Clinical

Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG

2016
Author: Confino H, et al.
View Publication

Pre-Clinical

Tumor ablation by intratumoral Ra-224 loaded wires induces anti-tumor immunity against experimental metastatic tumors

2015
Author: Confino H, et al.
View Publication

Pre-Clinical

Ablation of experimental colon cancer by intratumoral 224 Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy

2015
Author: Reitkopf-Brodutch S, et al.
View Publication

Pre-Clinical

Activation of local and systemic anti‑tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments

2014
Author: Keisari Y, et al.
View Publication

Pre-Clinical

Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation

2013
Author: Milrot E, et al.
View Publication

Pre-Clinical

Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224Radium-loaded wires releasing alpha-emitting atoms

2012
Author: Horev-Drori G, et al.
View Publication

Pre-Clinical

Intratumoral Ra-224-loaded wires spread alpha emitting atoms inside solid human tumors in athymic mice and can achieve local tumor control

2012
Author: Cooks. T, et al.
View Publication

Pre-Clinical

Comparative in vitro microdosimetric study of murine and human-derived cancer cells exposed to alpha particles

2011
Author: Lazarov E, et al.
View Publication

Physics

Treatment of solid tumors by alpha emitters released from 224Ra-loaded sources – internal dosimetry analysis

2010
Author: Arazi A
View Publication

Pre-Clinical

Interstitial wires releasing diffusing alpha-emitters combined with chemotherapy improved local tumor control and survival in squamous cell carcinoma bearing mice

2009
Author: Cooks. T, et al.
View Publication

Pre-Clinical

Local control of lung derived tumors by diffusing alpha-emitting atoms released from intratumoral wires loaded with Radium-224

2009
Author: Cooks. T, et al.
View Publication

Pre-Clinical

Growth retardation and destruction of experimental squamous cell carcinoma by interstitial radioactive wires releasing diffusing alpha-emitting atoms

2008
Author: Cooks. T, et al.
View Publication

Physics

Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters

2007
Author: Arazi A
View Publication

Media

The Big Biz Show

Alpha Tau CFO Raphi Levy breaks down Alpha DaRT on The Big Biz Show

View

Channel 11

The Next Big Thing – Interview with Uzi Sofer, Alpha Tau CEO on Alpha Tau, Alpha DaRT and leadership

View

Channel 10

Tel Aviv – New York – Interview with Alpha Tau CEO following regulatory approval for Alpha DaRT in Japan

View

Smart Money Circle Show Hosted By Adam Sarhan

Smart Money Circle Show Hosted By Adam Sarhan – Interview with Alpha Tau CFO, Raphi Levy

View

Florida Weekly

How recurrent disease is driving the search for new treatment options

View

Dermatology Times

Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT

View

BioSpace

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

View

Cancer Network

FDA Receives Pre-Market Approval Module for Novel Recurrent CSCC Therapy

View

Cleveland.com

Brain tumor breakthrough: First patient receives Alpha DaRT radiation at OSU

View

BioSpace

Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

View

Rare Cancer

1st trial participant receives Alpha DaRT radiation therapy for glioblastoma

View

RTT News

Alpha Tau Treats First U.S. Brain Cancer Patient With Alpha DaRT; Shares Surge On Breakthrough

View
Load More